$6.000
-0.212 (-3.54%)At close
FHTX News
FHTX Events
Foghorn Therapeutics Q2 Revenue $16.07M
Reports Q2 revenue $16.07M, consensus $7.93M. "Our FHD-909 trial in collaboration with Lilly continues to advance through dose escalation, with an initial focus on SMARCA4-mutant NSCLC, a setting where effective treatment options remain limited and outcomes poor," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics.
Foghorn Therapeutics Q1 Revenue $3.27M, Below Expectations
Reports Q1 revenue $3.27M, consensus $7.94M. "Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, where outcomes remain especially poor and deteriorate with later lines of therapy," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. "At this year's American Association for Cancer Research Annual Meeting, we presented compelling preclinical data demonstrating the potential of FHD-909 in combination with an anti-PD-1 antibody to drive complete, durable tumor regression and anti-tumor immune memory."
Foghorn Therapeutics Presents Preclinical Data for FHD-909
Foghorn Therapeutics presented new preclinical data for Selective SMARCA2 inhibitor FHD-909 showing complete and durable tumor regression together with anti-tumor immune memory following combination treatment with an anti-PD-1 antibody in preclinical syngeneic mouse models. The company also reported new preclinical data for its Selective CBP and Selective EP300 degrader programs, demonstrating favorable efficacy and safety profiles across a range of difficult-to-treat cancers, in addition to progress with its Selective ARID1B degrader program. These data were unveiled in multiple oral and poster presentations at the 2026 American Association for Cancer Research Annual Meeting. Key highlights include: Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models; Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer; Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy ; Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability
Foghorn Therapeutics Appoints Ryan Maynard as CFO
Foghorn Therapeutics announced that Ryan Maynard will join the company as Chief Financial Officer, CFO, on February 23, 2026. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. Prior to joining Foghorn, Maynard was most recently at Cara Therapeutics
Foghorn Therapeutics announces Q3 earnings per share of 25 cents, below consensus estimate of 30 cents.
Reports Q3 revenue $8.153M, consensus $6.2M. "This quarter marked continued execution across our portfolio, reinforcing our leadership in developing novel precision therapies with broad applicability across cancers," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "FHD-909, in collaboration with Lilly, is advancing in a Phase 1 dose escalation trial for the treatment of SMARCA4-mutated cancers with a focus on NSCLC. Based on our preclinical monotherapy and combination data, we are enthusiastic about the development of FHD-909 with the goal of developing it as a front-line therapy in NSCLC. Our strategic collaboration with Lilly provides the necessary strategic and financial resources to develop FHD-909."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.